我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

辛伐他汀抑制肺动脉高压大鼠肺动脉内COX-2的表达

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2009年第5期
页码:
625-628，633
栏目:
基础研究
出版日期:
2009-07-14

文章信息/Info

Title:
Effect of simvastatin on expression of cyclooxygenase-2 in a rat model of pulmonary artery hypertension
作者:
刘忠强; 刘斌; 余莉; 王晓琴; 王娟; 刘瀚旻
四川大学华西第二医院小儿心血管科，四川 成都 610041
Author(s):
LIU Zhong-qiang;  LIU Bin;  YU Li;  WANG Xiao-qin;  WANG Juan;  LIU Han-min
Department of Pediatric Angiocardiology, Second West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China
关键词:
3-羟基-3-甲基戊二酰辅酶A还原酶; 环氧化酶-2; 肺动脉高压; 辛伐他汀
Keywords:
HMG-COA;  cyclooxygenase-2;  pulmonary artery hypertension;  simvastatin
分类号:
R972.4
DOI:
-
文献标识码:
A
摘要:
目的: 探讨3-羟基-3-甲基戊二酰辅酶A还原酶（HMG-COA）抑制剂辛伐他汀对肺动脉高压（PAH）大鼠环氧合酶（COX-2）的影响。方法: 雄性SD大鼠30只，随机分为正常对照组、PAH模型组和辛伐他汀干预组，每组10只。用PM-8000型多参数监护仪及Elastin Van Gieson染色法，分别测定各组大鼠的平均肺动脉压力及肺小动脉新生内膜增殖度和平均血管阻塞计分（VOS）的改变。用免疫组化染色法和荧光定量PCR法，测定肺组织中的COX-2在蛋白和基因的水平上表达的差异。结果: PAH模型组大鼠的平均肺动脉压力、肺小动脉新生内膜增殖度和VOS的改变，均较正常对照组显著增加（P<0.05），其COX-2在蛋白和基因的水平上的表达都明显高于正常对照组（P<0.05）。辛伐他汀干预后，大鼠的平均肺动脉压力、肺小动脉新生内膜增殖度和VOS，均较PAH模型组显著减少（P<0.05），COX-2在蛋白和基因的水平上的表达都明显低于PAH模型组（P<0.05）。结论: 辛伐他汀可抑制肺动脉内COX-2的表达来抑制PAH形成。
Abstract:
AIM: To explore the effect of simvastatin, an inhibitor of HMG-COA, on the expression of cyclooxygenase-2 (COX-2) in a rat model of pulmonary artery hypertension (PAH). METHODS: Thirty male Sprague Dawley rats were randomized into three groups equally: control group, PAH model group and treatment group with intervention of simvastatin. Changes of mean pulmonary arterial pressure (mPAP), endomembrane proliferation in the pneumono-arteriole and the average vascular occlusion scores (VOS) were measured. Gene and protein expression of COX-2 were also measured, respectively, by fluorescent quantitation PCR and immunohistochemistry. RESULTS: mPAP, pneumono-arteriole and VOS increased significantly in the PAH model group compared with those in the control group (P<0.05). Expression of COX-2 both at the level of gene and protein was significantly higher in the PAH model group than in the control group (P<0.05). With the intervention of simvastatin, mPAP and endomembrane proliferation in the pneumono-arteriole and VOS decreased dramatically (P<0.05) compared with those in the model group (P<0.05). CONCLUSION: PAH model has been induced successfully by pneumonoresection+monocrotaline (MCT) and simvastatin may hamper PAH partly by inhibiting the expression of COX-2 in pulmonary artery.

参考文献/References

［1］ Nishimura T, Faul JL, Berry GJ, et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats［J］. Am J Respir Crit Care Med, 2002,166(10):1403-1408.

［2］ Girgis RE, Mozammel S, Champion HC, et al. Regression of chronic hypoxic pulmonary hypertension by simvastatin［J］. Am J Physiol Lung Cell Mol Physiol, 2007, 292(5):L1105-L1110.

［3］ Jiang BH, Tawara S, Abe K, et al. Acute vasodilatou effect of fasudil,a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats［J］. J Cardiovasc Pharmacol, 2007, 49(2):85-89.

［4］ Dannenberg AJ, Altorki NK, Boyle JO, et al. Cyclooxygenase 2: a pharmacological target for the prevention of cancer［J］. Lancet Oncol, 2001, 2(9):544-551.

［5］ Lam CF, Peterson TE, Croatt AJ, et al. Functional adaptation and remodeling of pulmonary artery in flow-induced pulmonary hypertension［J］. Am J Physiol Heart Circ Physiol, 2005, 289(6):H2334-H2341.

［6］ Pidgeon GP, Tamosiuniene R, Chen G, et al. Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2［J］. Circulation, 2004, 110(17):2701-2707.

［7］ Fike CD, Kaplowitz MR, Zhang Y, et al. Cyclooxygenase-2 and an early stage of chronic hypoxia-induced pulmonary hypertension innewborn pigs［J］. J Appl Physiol, 2005, 98(3):1111-1118.

［8］ Shepherd J. The statin era： in search of the ideal lipid regulating agent［J］. Heart, 2001, 85(3):259-264.

［9］ Gomez-Hernandez A, Sanchez-Galan E, Martin-Ventura JL, et al. Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: potential implications for plaque stabilization［J］. J Cardiovasc Pharmacol, 2006, 47(1):60-69.

备注/Memo

备注/Memo:
收稿日期：2008-6-16.基金项目：国家自然科学基金项目资助（30300145） 通讯作者：刘瀚旻，副教授，主要从事小儿心血管基础研究Email:myuxuan@163.net 作者简介：刘忠强，住院医师，硕士Email pediatr@yahoo.cn
更新日期/Last Update: 2009-07-22